Open AccessMethylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
Author(s) -
К. Б. Мирзаев,
Ю. Ю. Киселёв,
Д. А. Сычёв
Publication year - 2020
Publication title -
kačestvennaâ kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8473
pISSN - 2588-0519
DOI - 10.37489/2588-0519-2020-s4-23-27
Subject(s) - tocilizumab , medicine , methylprednisolone , acute respiratory distress , covid-19 , respiratory distress , intensive care medicine , anesthesia , lung , rheumatoid arthritis , disease , infectious disease (medical specialty)
No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, when interleukin-6 blockers (tocilizumab, sarilumab) are unavailable.